Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1956 1
1961 1
1963 5
1964 3
1967 5
1969 4
1970 5
1971 3
1972 2
1973 3
1974 4
1975 3
1976 3
1977 3
1978 4
1979 8
1980 2
1981 3
1982 5
1983 3
1984 7
1985 9
1986 6
1987 7
1988 4
1989 7
1990 11
1991 9
1992 11
1993 8
1994 17
1995 15
1996 13
1997 16
1998 9
1999 17
2000 10
2001 11
2002 13
2003 12
2004 10
2005 11
2006 14
2007 18
2008 22
2009 24
2010 17
2011 21
2012 40
2013 40
2014 46
2015 50
2016 53
2017 53
2018 50
2019 59
2020 65
2021 68
2022 6
Text availability
Article attribute
Article type
Publication date

Search Results

840 results
Results by year
Filters applied: . Clear all
Page 1
Mitochondrial Stasis Reveals p62-Mediated Ubiquitination in Parkin-Independent Mitophagy and Mitigates Nonalcoholic Fatty Liver Disease.
Yamada T, Murata D, Adachi Y, Itoh K, Kameoka S, Igarashi A, Kato T, Araki Y, Huganir RL, Dawson TM, Yanagawa T, Okamoto K, Iijima M, Sesaki H. Yamada T, et al. Among authors: igarashi a. Cell Metab. 2018 Oct 2;28(4):588-604.e5. doi: 10.1016/j.cmet.2018.06.014. Epub 2018 Jul 12. Cell Metab. 2018. PMID: 30017357 Free PMC article.
Delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with moderate to severe atopic dermatitis: A phase 3, randomized, double-blind, vehicle-controlled study and an open-label, long-term extension study.
Nakagawa H, Nemoto O, Igarashi A, Saeki H, Kaino H, Nagata T. Nakagawa H, et al. Among authors: igarashi a. J Am Acad Dermatol. 2020 Apr;82(4):823-831. doi: 10.1016/j.jaad.2019.12.015. Epub 2020 Feb 3. J Am Acad Dermatol. 2020. PMID: 32029304 Free article. Clinical Trial.
Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis: A Phase 3 Randomized Clinical Trial.
Blauvelt A, Leonardi CL, Gooderham M, Papp KA, Philipp S, Wu JJ, Igarashi A, Flack M, Geng Z, Wu T, Camez A, Williams D, Langley RG. Blauvelt A, et al. Among authors: igarashi a. JAMA Dermatol. 2020 Jun 1;156(6):649-658. doi: 10.1001/jamadermatol.2020.0723. JAMA Dermatol. 2020. PMID: 32267471 Free PMC article. Clinical Trial.
Five-year efficacy and safety of tildrakizumab in patients with moderate-to-severe psoriasis who respond at week 28: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2).
Thaci D, Piaserico S, Warren RB, Gupta AK, Cantrell W, Draelos Z, Foley P, Igarashi A, Langley RG, Asahina A, Young M, Falqués M, Pau-Charles I, Mendelsohn AM, Rozzo SJ, Reich K. Thaci D, et al. Among authors: igarashi a. Br J Dermatol. 2021 Aug;185(2):323-334. doi: 10.1111/bjd.19866. Epub 2021 May 4. Br J Dermatol. 2021. PMID: 33544883 Clinical Trial.
Long-term efficacy and safety of tildrakizumab for moderate-to-severe psoriasis: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2) through 148 weeks.
Reich K, Warren RB, Iversen L, Puig L, Pau-Charles I, Igarashi A, Ohtsuki M, Falqués M, Harmut M, Rozzo S, Lebwohl MG, Cantrell W, Blauvelt A, Thaçi D. Reich K, et al. Among authors: igarashi a. Br J Dermatol. 2020 Mar;182(3):605-617. doi: 10.1111/bjd.18232. Epub 2019 Jul 18. Br J Dermatol. 2020. PMID: 31218661 Free PMC article.
840 results